

March 18, 2026

The Honorable Jamieson Greer  
Ambassador  
United States Trade Representative  
600 17th Street NW,  
Washington, DC 20508

The Honorable George Glass  
Ambassador  
Embassy of Japan  
2520 Massachusetts Ave NW,  
Washington, DC 20008

Dear Ambassador Greer and Ambassador Glass:

On behalf of the undersigned organizations, we write to urge the Trump administration to address deeply destructive regulations and price controls on the biopharmaceutical sector during upcoming discussions with Japanese Prime Minister Sanae Takaichi during her visit to Washington, D.C.

The United States and Japan share one of the world's strongest economic and strategic partnerships, and that relationship continues to build. Economic ties between the two nations have resulted in Japan investing in new [energy infrastructure](#), [manufacturing plants](#), and [critical mineral processing facilities](#). As President Trump has rightly noted, the U.S. and Japan are allies "at the strongest level" and trade between the two countries has benefited the citizens of both.

While recent Japanese investments in the U.S. are crucial to strengthening American supply chains, U.S. officials must pay close attention to the biopharmaceutical sector and how foreign regulations can hamper trade. For far too long, wealthy nations such as Japan have benefited from American medical innovation while implementing costly price controls on medications that result in higher prices on U.S. consumers.

Japan relies heavily on government price-setting policies that artificially suppress the price of innovative medicines. As a result, Japan pays [roughly half](#) as much as Americans do for new treatments—even when accounting for differences in economic output. These policies shift a disproportionate share of the cost of pharmaceutical research and development onto American patients and taxpayers, draining tens of billions of dollars from the innovation ecosystem each year and diverting resources away from job creation and biopharmaceutical development.

This regulatory and economic imbalance is not sustainable. Wealthy allied nations need to end costly price controls that stymie groundbreaking medicines and cures and increase costs on American households. Patients in those countries would also benefit, with greater access to cutting-edge cures and treatments.

As the administration strives to strengthen America's economic partnerships, we encourage you to leverage ongoing trade negotiations to ensure that price controls do not thwart American medical innovation in global markets. These short-sighted regulatory policies harm everyone and weaken pivotal trade relationships.

Thank you for your continued leadership on this important issue.

Signed,

David Williams  
President  
Taxpayers Protection Alliance

Pete Sepp  
President  
National Taxpayers Union

Grover Norquist  
President  
Americans for Tax Reform

Phil Kerpen  
President  
American Commitment

Stephen Moore  
Co-Founder  
Unleash Prosperity Now

Gerard Scimeca  
Chairman  
Consumer Action for a Strong Economy

Karen Kerrigan  
President & CEO  
Small Business & Entrepreneurship Council

Anthony J. Zagotta  
President  
Center for American Principles

Kent Kaiser, Ph.D.  
Executive Director  
Trade Alliance to Promote Prosperity

James Edwards, Ph.D.  
Founder and Executive Director  
Conservatives for Property Rights

Daniel J. Mitchell  
President  
Center for Freedom and Prosperity

Dee Stewart  
President  
Americans for a Balanced Budget

Tom Schatz  
President  
Citizens Against Government Waste

Ginevra Joyce-Myers  
Executive Director  
Center for Innovation and Free Enterprise

Ryan Ellis  
President  
Center for a Free Economy

Jeffrey Mazzella  
President  
Center for Individual Freedom

George Landrith  
President  
Frontiers of Freedom

John Shelton  
Vice President of Policy  
Advancing American Freedom